EUVIMEDEUVIMED entdecken
Crossref

Lenvatinib as Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: CT ‐Based Selection and Outcomes From a 23‐Patient Cohort

J J Santivañez iD, C Betancourt, C García, J G Sánchez, D Figueroa-Bohorquez, L Mendieta, A Román-González, A Sanabria iD

Head & Neck · 2026-08 · 48 (8) · 2009-2018

DOI: 10.1002/hed.70221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, online erschienen am 05.03.2026. Verfasst von J J Santivañez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Surgery Section, University of Antioquia, Medellin, Colombia. Hauptthemen laut MEDLINE: Phenylurea Compounds, Quinolines, Thyroid Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy and its incidence has increased in recent decades. In locally advanced thyroid carcinoma (LATC), disease may be unresectable or require highly morbid surgical procedures. Lenvatinib has demonstrated rapid tumor shrinkage in radioiodine‐refractory DTC, suggesting a potential role as neoadjuvant therapy to facilitate surgical management. However, optimal patient selection for this approach remains unclear. We evaluated the role of lenvatinib as neoadjuvant therapy to achieve resectability or surgical de‐escalation in patients with locally advanced or recurrent DTC, using computed tomography (CT)‐based anatomical complexity scores for patient selection.

Methods

A retrospective study was conducted in 23 patients with locally advanced or recurrent DTC treated with neoadjuvant lenvatinib at a tertiary referral center. Based on pretreatment CT findings, patients were classified as unresectable ( n = 12) or resectable only through major surgery (RMS) ( n = 11). Disease complexity was assessed using the MMM surgical morbidity and complexity score and the thyroid neck morbidity and complexity (TNMC) classification. Radiologic response was evaluated according to RECIST 1.1 criteria.

Results

Median lenvatinib treatment duration was 10 months (range 2–25). Partial or complete radiologic response was achieved in 16 patients (69%). Surgery was performed in 13 patients (56%): 7/12 (58%) from the initially unresectable group and 6/11 (55%) from the RMS group. Among unresectable cases undergoing surgery, complete resection was achieved in 6/7 (86%). In the RMS group, surgical de‐escalation was achieved in 5/6 (83%), avoiding procedures such as laryngectomy or pharyngolaryngectomy. Overall, R0/R1 margins were obtained in 11/13 operated patients (85%). The 24‐month overall survival was 89.7%, and treatment was generally well tolerated.

Conclusions

Neoadjuvant lenvatinib enabled conversion to resectability and meaningful surgical de‐escalation in selected patients with LATC, with acceptable toxicity. CT‐based complexity scores were useful tools for patient selection. Prospective multicenter studies integrating molecular profiling are needed to refine indications and optimal treatment duration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsQuinolinesThyroid NeoplasmsNeoadjuvant TherapyAntineoplastic AgentsHumansFemaleMaleRetrospective StudiesMiddle AgedTomography, X-Ray ComputedAdultAgedTreatment OutcomePatient SelectionCohort StudiesThyroidectomy

Stichwörter der Autor:innen

differentiated thyroid carcinomalenvatiniblocally advanced thyroid cancermultikinase inhibitorsneoadjuvant therapysurgical de‐escalationsurgical resection

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesAntineoplastic Agents

Autor:innen und Institutionen

  • Head and Neck Surgery Section, University of Antioquia, Medellin, Colombia.
  • Centro de Excelencia en Enfermedades de Cabeza y Cuello, CEXCA, Medellín, Colombia.
  • Head and Neck Surgery Section, Hospital Alma Máter de Antioquia, Medellín, Colombia.
  • Head and Neck Surgery Section, Hospital San Vicente Fundación, Medellín, Colombia.
  • Endocrine Section, University of Antioquia, Medellin, Colombia.

ORCID-Profile: J J Santivañez, A Sanabria

Zitieren

APA

Santivañez, J. J., Betancourt, C., García, C., Sánchez, J. G., Figueroa-Bohorquez, D., Mendieta, L., Román-González, A., & Sanabria, A. (2026). Lenvatinib as Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: CT ‐Based Selection and Outcomes From a 23‐Patient Cohort. Head & Neck, 48(8), 2009-2018. https://doi.org/10.1002/hed.70221

Vancouver

Santivañez JJ, Betancourt C, García C, Sánchez JG, Figueroa-Bohorquez D, Mendieta L, et al. Lenvatinib as Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: CT ‐Based Selection and Outcomes From a 23‐Patient Cohort. Head & Neck. 2026;48(8):2009-2018. doi:10.1002/hed.70221

BibTeX
@article{Santivaez2026,
  author = {Santivañez, J J and Betancourt, C and García, C and Sánchez, J G and Figueroa-Bohorquez, D and Mendieta, L and Román-González, A and Sanabria, A},
  title = {Lenvatinib as Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: CT ‐Based Selection and Outcomes From a 23‐Patient Cohort},
  journal = {Head & Neck},
  year = {2026},
  volume = {48},
  number = {8},
  pages = {2009--2018},
  doi = {10.1002/hed.70221}
}
Kostenlos starten →